Neo Ivy Capital Management Takes $318,000 Position in Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR)

Neo Ivy Capital Management acquired a new position in Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR - Free Report) in the fourth quarter, according to its most recent filing with the Securities and Exchange Commission. The institutional investor acquired 16,920 shares of the biotechnology company's stock, valued at approximately $318,000.

Several other institutional investors have also recently modified their holdings of the company. R Squared Ltd purchased a new position in shares of Arrowhead Pharmaceuticals during the 4th quarter valued at about $38,000. Van ECK Associates Corp raised its holdings in shares of Arrowhead Pharmaceuticals by 72.3% during the 4th quarter. Van ECK Associates Corp now owns 2,978 shares of the biotechnology company's stock valued at $56,000 after buying an additional 1,250 shares in the last quarter. KBC Group NV raised its holdings in shares of Arrowhead Pharmaceuticals by 45.9% during the 4th quarter. KBC Group NV now owns 5,224 shares of the biotechnology company's stock valued at $98,000 after buying an additional 1,644 shares in the last quarter. Envestnet Portfolio Solutions Inc. purchased a new position in shares of Arrowhead Pharmaceuticals during the 4th quarter valued at about $190,000. Finally, First Citizens Bank & Trust Co. purchased a new position in shares of Arrowhead Pharmaceuticals during the 4th quarter valued at about $205,000. 62.61% of the stock is currently owned by institutional investors.

Arrowhead Pharmaceuticals Trading Up 1.6%

Shares of Arrowhead Pharmaceuticals stock traded up $0.24 during trading on Tuesday, reaching $15.37. 1,281,301 shares of the stock were exchanged, compared to its average volume of 1,504,745. The company has a quick ratio of 6.09, a current ratio of 6.09 and a debt-to-equity ratio of 7.27. The stock's fifty day moving average is $13.32 and its 200 day moving average is $17.56. The firm has a market cap of $2.12 billion, a price-to-earnings ratio of -2.97 and a beta of 0.89. Arrowhead Pharmaceuticals, Inc. has a 1 year low of $9.57 and a 1 year high of $30.41.

Arrowhead Pharmaceuticals (NASDAQ:ARWR - Get Free Report) last posted its earnings results on Monday, May 12th. The biotechnology company reported $2.75 earnings per share for the quarter, topping analysts' consensus estimates of ($0.06) by $2.81. The firm had revenue of $542.71 million for the quarter, compared to analysts' expectations of $116.27 million. During the same quarter in the prior year, the company posted ($1.02) earnings per share. As a group, equities research analysts expect that Arrowhead Pharmaceuticals, Inc. will post -2.42 earnings per share for the current fiscal year.

Insiders Place Their Bets

In other Arrowhead Pharmaceuticals news, CEO Christopher Richard Anzalone sold 40,322 shares of the firm's stock in a transaction dated Wednesday, April 9th. The shares were sold at an average price of $10.07, for a total value of $406,042.54. Following the completion of the sale, the chief executive officer now directly owns 4,022,055 shares in the company, valued at $40,502,093.85. This trade represents a 0.99% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available at this link. Insiders sold 275,880 shares of company stock worth $4,034,037 over the last three months. Company insiders own 4.30% of the company's stock.

Wall Street Analysts Forecast Growth

ARWR has been the topic of a number of research reports. Wall Street Zen raised Arrowhead Pharmaceuticals from a "sell" rating to a "hold" rating in a report on Thursday, May 22nd. B. Riley restated a "buy" rating and set a $38.00 price target (down from $51.00) on shares of Arrowhead Pharmaceuticals in a research report on Friday, February 14th. Citigroup cut their price target on shares of Arrowhead Pharmaceuticals from $21.00 to $17.00 and set a "neutral" rating for the company in a research report on Tuesday, May 13th. Royal Bank of Canada restated an "outperform" rating and set a $42.00 price target on shares of Arrowhead Pharmaceuticals in a research report on Tuesday, February 11th. Finally, Chardan Capital restated a "buy" rating and set a $60.00 price target on shares of Arrowhead Pharmaceuticals in a research report on Tuesday, May 13th. Four investment analysts have rated the stock with a hold rating and six have given a buy rating to the company. According to data from MarketBeat.com, Arrowhead Pharmaceuticals currently has an average rating of "Moderate Buy" and an average target price of $42.13.

About Arrowhead Pharmaceuticals

Arrowhead Pharmaceuticals, Inc develops medicines for the treatment of intractable diseases in the United States. The company's products in pipeline includes Plozasiran, which is in Phase 2b and one Phase 3 clinical trial to treat hypertriglyceridemia, mixed dyslipidemia, and chylomicronemia syndrome; Zodasiran that is in Phase 2b clinical trial for the treatment of dyslipidemia and hypertriglyceridemia; ARO-PNPLA3, which is in Phase 1 clinical trial to treat patients with non-alcoholic steatohepatitis; ARO-RAGE that is in Phase 1/2a clinical trial to treat inflammatory pulmonary conditions; and ARO-MUC5AC, which is in Phase 1/2a clinical trial to treat muco-obstructive pulmonary diseases.